COVID-19 vaccine safety

Authors

DOI:

https://doi.org/10.17843/rpmesp.2021.384.9308

Keywords:

Vaccine, Coronavirus, SARS-CoV-2, Spike Glycoprotein, Immunogenicity, Efficacy, Adverse events, Clinical Trial, Phase III, Pandemics

Abstract

The development and production of safe and effective vaccines against coronavirus disease 2019 (COVID-19) provides hope for controlling the current pandemic. Adverse events following immunization are unwanted responses or unintended events that must be carefully monitored, as all vaccines, including those developed against SARS-CoV-2, are required to meet safety criteria for administration in humans. Information was collected from the PubMed/Medline database during the months of August 2020 to November 2021. Most adverse events reported in clinical trials were mild or moderate; however, thrombotic events associated with some viral vector-based vaccines against COVID-19 were identified in follow-up studies, although completion of the various ongoing studies and post-marketing surveillance is required to determine all potential adverse events, as well as those of special interest.

Downloads

Download data is not yet available.

Published

2021-12-22

Issue

Section

Review

How to Cite

1.
Chaparro Mérida NA, Samper DM, Franco Lacato AO. COVID-19 vaccine safety. Rev Peru Med Exp Salud Publica [Internet]. 2021 Dec. 22 [cited 2024 May 18];38(4):634-42. Available from: https://rpmesp.ins.gob.pe/index.php/rpmesp/article/view/9308

Most read articles by the same author(s)